Results 171 to 180 of about 6,710,280 (212)

Cloxacillin- and Terbinafine-Associated Mixed Drug-Induced Liver Injury: Contrasting Clinical Outcomes and Causality Assessment Using the Updated RUCAM. [PDF]

Case Reports Hepatol
Casòliva EO, Montero AJA, de Carvalho A, Morer SM, Arvaniti P.   +4 more
europepmc   +1 more source

Analysis of risk factors for anti-tuberculous drug-induced liver injury in treatment-naïve pulmonary tuberculosis patients with different Traditional Chinese Medicine syndromes: a retrospective study. [PDF]

J Tradit Chin Med
Huan C, Chunjun XU, Zuohu N, Shuo L, Ye L.   +4 more
europepmc   +1 more source

Exploring Avenues of Predicting Drug-Induced Liver Injury. [PDF]

Chem Res Toxicol
Liyanarachchi DP.
europepmc   +1 more source

Multicenter Evaluation of Large Language Models Versus Hepatologists for Prognostic Prediction in Drug-Induced Liver Injury. [PDF]

Liver Int
Fu H, Du Y, Zhao G, Xiao Y, Song S, Zang X, Zhou T, Zhuang Y, Mo R, Lai R, Xie Q.   +10 more
europepmc   +1 more source

Drug Induced Liver Injury – A 2023 Update

Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2023
Drug-Induced Liver Injury (DILI) constitutes hepatic damage attributed to drug exposure. DILI may be categorized as hepatocellular, cholestatic or mixed and might also involve immune responses. When DILI occurs in dose-dependent manner, it is referred to
Ali Kermanizadeh, Asha Guraka
exaly   +2 more sources

A New Framework for Advancing in Drug-Induced Liver Injury Research. The Prospective European DILI Registry

Liver International, 2023
BACKGROUND & AIMS No multi-national prospective study of drug-induced liver injury (DILI) has originated from Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported ...
Ismael Álvarez-Álvarez, Sabine Weber, María Isabel Lucena González   +2 more
exaly   +2 more sources